These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33206247)

  • 1. Contrastive Studies of Cytarabine/Daunorubicin Dual-Loaded Liposomes Prepared by pH Gradient and Cu
    Zhang J; Zhou L; Zhang Y; He H; Yin T; Gou J; Wang Y; Tang X
    AAPS PharmSciTech; 2020 Nov; 21(8):325. PubMed ID: 33206247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of intermolecular interactions on the stability and in vitro drug release of daunorubicin/cytarabine co-loaded liposome.
    Liu B; Zhang J; Gou J; Zhang Y; He H; Yin T; Zheng Z; Tang X
    Colloids Surf B Biointerfaces; 2022 Sep; 217():112673. PubMed ID: 35780612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research on the preparation process of the cytarabine/daunorubicin dual-encapsulation liposome and its physicochemical properties and performances in vitro/vivo.
    Liu B; Zhang J; Liu Z; Wang P; Zhang Y; He H; Yin T; Gou J; Tang X
    Int J Pharm; 2023 Nov; 646():123500. PubMed ID: 37820944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.
    Tardi P; Johnstone S; Harasym N; Xie S; Harasym T; Zisman N; Harvie P; Bermudes D; Mayer L
    Leuk Res; 2009 Jan; 33(1):129-39. PubMed ID: 18676016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: implications for liposome-encapsulated daunorubicin.
    Verdonck LF; Lokhorst HM; Roovers DJ; van Heugten HG
    Leuk Res; 1998 Mar; 22(3):249-56. PubMed ID: 9619916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD123/CD33 dual-antibody modified liposomes effectively target acute myeloid leukemia cells and reduce antigen-negative escape.
    Sun S; Zou H; Li L; Liu Q; Ding N; Zeng L; Li H; Mao S
    Int J Pharm; 2019 Sep; 568():118518. PubMed ID: 31319147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties.
    Mayer LD; Tardi P; Louie AC
    Int J Nanomedicine; 2019; 14():3819-3830. PubMed ID: 31213803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triggering liposomal drug release with a lysosomotropic agent.
    Xiong S; Li H; Yu B; Wu J; Lee RJ
    J Pharm Sci; 2010 Dec; 99(12):5011-8. PubMed ID: 20821395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins.
    Candoni A; Michelutti A; Simeone E; Damiani D; Baccarani M; Fanin R
    Eur J Haematol; 2006 Oct; 77(4):293-9. PubMed ID: 16856922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon.
    Hou H; Nieto A; Ma F; Freeman WR; Sailor MJ; Cheng L
    J Control Release; 2014 Mar; 178():46-54. PubMed ID: 24424270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse.
    Bayne WF; Mayer LD; Swenson CE
    J Pharm Sci; 2009 Jul; 98(7):2540-8. PubMed ID: 19009594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. pH-Sensitive Liposomes for Enhanced Cellular Uptake and Cytotoxicity of Daunorubicin in Melanoma (B16-BL6) Cell Lines.
    Alrbyawi H; Poudel I; Annaji M; Boddu SHS; Arnold RD; Tiwari AK; Babu RJ
    Pharmaceutics; 2022 May; 14(6):. PubMed ID: 35745701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment.
    Nikanjam M; Capparelli EV; Lancet JE; Louie A; Schiller G
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):171-178. PubMed ID: 29167924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin.
    Dicko A; Kwak S; Frazier AA; Mayer LD; Liboiron BD
    Int J Pharm; 2010 May; 391(1-2):248-59. PubMed ID: 20156541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation, therapeutic efficacy and intratumoral localization of targeted daunorubicin liposomes conjugating folate-PEG-CHEMS.
    Xiong S; Yu B; Wu J; Li H; Lee RJ
    Biomed Pharmacother; 2011 Feb; 65(1):2-8. PubMed ID: 21177069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin.
    Seipelt G; Hofmann WK; Martin H; Wassmann B; Boehme A; Ottmann OG; Hoelzer D
    Ann Hematol; 1998; 76(3-4):145-51. PubMed ID: 9619732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.
    Mandelli F; Petti MC; Ardia A; Di Pietro N; Di Raimondo F; Ganzina F; Falconi E; Geraci E; Ladogana S; Latagliata R
    Eur J Cancer; 1991; 27(6):750-5. PubMed ID: 1829918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts.
    Lim WS; Tardi PG; Dos Santos N; Xie X; Fan M; Liboiron BD; Huang X; Harasym TO; Bermudes D; Mayer LD
    Leuk Res; 2010 Sep; 34(9):1214-23. PubMed ID: 20138667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release.
    Li C; Cui J; Li Y; Wang C; Li Y; Zhang L; Zhang L; Guo W; Wang J; Zhang H; Hao Y; Wang Y
    Eur J Pharm Sci; 2008 Aug; 34(4-5):333-44. PubMed ID: 18573336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of multi-functional liposomes containing daunorubicin and emetine for treatment of acute myeloid leukaemia.
    Myhren L; Nilssen IM; Nicolas V; Døskeland SO; Barratt G; Herfindal L
    Eur J Pharm Biopharm; 2014 Sep; 88(1):186-93. PubMed ID: 24747809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.